Stradefy Biosciences

Stradefy Biosciences is a private, preclinical-stage biotech developing a novel drug delivery platform called Bioadhesive Drug Carriers (BDCs). The technology aims to surpass the efficacy of ADCs by enabling higher drug loads and optimized retention and internalization in target cells. With lead candidates demonstrating in vivo proof of efficacy in oncology models, the company is advancing toward IND-enabling studies with a capital-efficient strategy. It is based on foundational research from Yale University and is backed by Elm Street Ventures.

Bioadhesive Drug Carriers (BDCs) engineered for enhanced cellular bioadhesion, uptake, and payload release, designed to surpass the capabilities of antibody-drug conjugates (ADCs).

Stradefy competes in the advanced drug conjugate and targeted delivery space, directly challenging developers of ADCs and other ligand-drug conjugates. It also faces competition from other novel nanoparticle and polymeric drug delivery platforms. Its differentiation hinges on proving superior bioadhesion and internalization properties.